NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma

Source: PharmaTimes Online, December 2021

The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.

NICE has issued guidance recommending Merck/MSD’s Keytruda (pembrolizumab) for routine commissioning, for use as a monotherapy for the adjuvant treatment of adults with stage 3 melanoma with lymph node involvement who have undergone complete resection.

“More than 16,000 people are diagnosed with Melanoma every year. There have been huge medical advances in the field of melanoma over the last decade and immunotherapy treatment has been an integral to this,” shared Susanna Daniels, CEO of Melanoma Focus. “Fear of recurrence of cancer is also a huge emotional burden for patients and families and in particular for the growing population of melanoma patients who are diagnosed at a younger age, with the majority of their life ahead of them (in the 15 to 44-year-olds age group, melanoma is the second most common cancer in males and the third most common in females).”

READ THE ORIGINAL FULL ARTICLE